SK Biopharma pockets W959bn from IPO
Drug developer SK Biopharmaceuticals priced its IPO high last Friday, netting W959.3bn ($792m), according to a source close to the deal.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: